-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16

Benzinga·05/05/2026 15:54:46
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.